Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28425724 | 0.88 | ACACB (0.38) | KDM4CACACBCA1CA2ACHE | |
| SCHEMBL20239341 | 0.85 | CA12 (0.47) | KDM4CCA1CA2SMN1; SMN2 | |
| SCHEMBL20239291 | 0.75 | ACACB (0.42) | ACACBCA1CA2NPC1RAB9A | |
| SCHEMBL20239152 | 0.74 | ACACB (0.46) | ACACB | |
| SCHEMBL28427913 | 0.73 | CA12 (0.46) | KDM4CCA1CA2SMN1; SMN2 | |
| SCHEMBL20259239 | 0.71 | SMN1; SMN2 (0.38) | ACACBCA1CA2SMN1; SMN2NPC1 | |
| SCHEMBL20472854 | 0.66 | CYP1A2 (0.39) | SMN1; SMN2 | |
| SCHEMBL20239157 | 0.65 | ALDH1A1 (0.36) | SMN1; SMN2 | |
| SCHEMBL20239339 | 0.65 | DGAT2 (0.37) | KDM4CCA1CA2SMN1; SMN2 | |
| SCHEMBL20239144 | 0.63 | SIRT2 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | KDM4C 4321/4885ACACB 152/4885CA1 4849/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | KDM4C 4238/4885ACACB 152/4885CA1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.